Incidental Pancreatic Cyst in an 82-Year-Old with Multiple Comorbidities
An 82-year-old man is referred after a CT abdomen performed for haematuria shows an incidental 18 mm cystic lesion in the body of the pancreas. He has ischaemic heart disease, stage 3 chronic kidney disease (eGFR 42), and atrial fibrillation on apixaban. He lives independently and walks 2 km daily. He is asymptomatic from the pancreatic lesion. There is no family history of pancreatic cancer. The CT shows a unilocular cyst without solid components, no main duct dilatation, and no calcification. His GP asks whether he needs an MRI, EUS, or nothing at all, and whether he should stop apixaban for any procedure.
1. How would you characterise this cyst and what is your initial management recommendation?
Read the worked answer
Characterisation:
- The description - unilocular, no solid component, no main duct dilatation, no calcification, 18 mm - is most consistent with a branch-duct IPMN or a small mucinous cystic neoplasm, but a serous cystadenoma or a simple retention cyst are also possible. Size <20 mm and absence of high-risk stigmata are reassuring.
- Under the revised Fukuoka/International Consensus guidelines, this lesion has no high-risk stigmata (no obstructive jaundice, no enhancing solid component, no main duct ≥10 mm) and no worrisome features (no cyst ≥30 mm, no thickened/enhancing wall, no main duct 5–9 mm, no non-enhancing mural nodule, no abrupt duct calibre change with distal atrophy, no lymphadenopathy).
Recommendation:
- MRI/MRCP with heavily T2-weighted sequences is the preferred next test to confirm the cystic nature, assess ductal communication, and look for mural nodules. It avoids ionising radiation and is safe with his CKD at eGFR 42 (though gadolinium should be used cautiously; a non-contrast MRCP is often sufficient).
- EUS is reserved for cases where MRI is non-diagnostic or where a mural nodule is suspected and sampling would change management.
- Surveillance rather than resection is appropriate: for a cyst <20 mm without worrisome features, imaging at 6 months and then every 1–2 years is reasonable, with the caveat that his age and comorbidity make aggressive surveillance optional.
- Do not biopsy or aspirate a small unilocular cyst without worrisome features; the yield is low and the risk of pancreatitis is real.
2. How does his age and comorbidity influence your decision, and how would you discuss this with him?
Read the worked answer
This is the crux of the case: the imaging finding is real, but the patient's life expectancy and fitness for pancreatic surgery are the dominant factors.
- Life expectancy and competing risk. At 82 with ischaemic heart disease, AF and CKD 3, his life expectancy is likely 5–10 years at best, and the risk of a small branch-duct IPMN progressing to malignancy over that horizon is low (single-digit percent per year at most, and lower for cysts <20 mm). The competing risk of cardiac death is substantial.
- Fitness for surgery. A pancreaticoduodenectomy or distal pancreatectomy carries 2–5% mortality and 30–50% morbidity even in fit patients, and higher in this group. If a worrisome feature developed, would he be a candidate? If not, aggressive surveillance has limited value.
- Shared decision-making. Explain the finding in plain language: it is a small fluid-filled pocket, most are benign, and the plan is to watch it rather than operate. Explain the surveillance schedule and the symptoms that should prompt earlier review (weight loss, jaundice, new pain, diabetes).
- Offer a choice. Some patients want surveillance; others, given the low risk and their age, prefer to stop after a confirmatory MRI. Document the discussion and the patient's preference.
- Address the apixaban question separately. No procedure is planned now. If EUS or biopsy were later required, apixaban would be withheld per local protocol (typically 48 hours for high-risk bleeding procedures, with bridging considered only in selected high thrombotic risk patients).